Sickle cell trait (SCT) is not a disease. Despite this, SCT status has been used as justification for unequal treatment in the military and college athletics, as cover for police misconduct, and as a rationale for inappropriate treatment of patients with SCT requiring stem cell collection.

This presentation will discuss current policies and review how many of them run contrary to the evidence.

Dr. Brian Carney is an Assistant Professor of Medicine at Harvard Medical School and an attending physician in the Division of Hematology and Hematologic Malignancies at Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts.

He also serves as Medical Director of Apheresis Services at BIDMC. In addition to the above roles, Dr. Carney is a clinical investigator with a particular interest in cancer-associated thrombosis and research relating to the safe and effective delivery of apheresis care.

He is currently the principal investigator for the SCT-Collect Study, a national
multi-center cohort study seeking to determine the incidence of complications in patients with known and possible sickle cell trait undergoing stem cell mobilization and collection.H